Is there a role for a pure noradrenergic drug in the treatment of depression?

European Neuropsychopharmacology

Volumn 7, Issue SUPPL. 1, 1997, Pages

  Montgomery, S A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Depression; Selective noradrenaline reuptake inhibitors (NARIs); Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DESIPRAMINE; DIPHENHYDRAMINE; FLUOXETINE; METIROSINE; NEUROTRANSMITTER; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CATECHOLAMINE SYNTHESIS; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRIVE; DRUG EFFICACY; HAMILTON SCALE; HUMAN; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SIDE EFFECT;

EID: 0030992193     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00414-8     Document Type: Conference Paper

References (37)

1. A. Aberg-Wistedt Controlled crossover study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant Acta. Psychiatr. Scand. 63 suppl. 290 1981 244 255
2. A. Aberg-Wistedt K.G. Jostell S.B. Ross D. Westerlund Effects of zimelidine and desipramine on serotonin and noradrenaline uptake mechanisms in relation to plasma concentrations and to therapeutic effects during treatment of depression Psychopharmacology 74 1981 297 305
3. B.M. Baron A.-M. Ogden B.W. Siegel I. Stegeman R.C. Ursillo M.W. Dudley Rapid down regulation of β-adrenoceptors by co-administration of desipramine and fluoxetine Eur. J. Pharmacol. 154 1988 125 134
4. C.M. Beasley B.E. Dornseif J.C. Bosomworth Fluoxetine and suicidality: absence of association in controlled depression trials Br. Med. J. 303 1991 685 692
5. H. Beckmann F.K. Goodwin Antidepressant response to TCAs and urinary MHPG in unipolar patients Arch. Gen. Psychiatry 32 1975 17 21
6. P.A. Bond F.A. Jenner G.A. Sampson Daily variations of the urine content of 3-methoxy-4-hydroxyphenylglycol Psychol. Med. 2 1972 81 85
7. G.E. Clerc P. Ruimy J. Verdeau Pailles A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia Int. Clin. Psychopharmacol. 9 1996 139 143
8. D.M. Cobbin B. Requin-Blow L.R. Williams W.O. Williams Urinary MHPG levels and tricyclic antidepressant drug selection Arch. Gen. Psychiatry 36 1979 1111 1115
9. A. Coppen R. Rama C.R. Ruthven B.L. Goodwin M. Sandler Urinary 4-hydroxy-3-methoxyphenylglycol is not a predictor for clinical response to amitriptyline in depressive illness Psychopharmacology 64 1979 95 97
10. P.L. Delgado D.S. Charney L.H. Price G.K. Aghajanian H. Landis G.R. Heninger Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan Arch. Gen. Psychiatry 47 1990 411 418
11. P.L. Delgado L.H. Price H.L. Miller R.M. Salomon J. Licinio J.H. Krystal G.R. Heninger D.S. Charney Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neuro-biology of depression Psychopharmacol. Bull. 27 1991 321 330
12. P.L. Delgado H.L. Miller R.M. Salomon J. Licinio G.R. Heninger A.J. Gelenberg D.S. Charney Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants Psychopharmacol. Bull. 29 1993 389 396
13. H.J. Gaertner F. Kreuter G. Scharek M. Brinkschulter U. Breyer-Pfaff Do urinary MHPG and plasma drug levels correlate with response to amitriptyline therapy? 1980 22–26 June CINP publ. Gothenberg, Sweden
14. J. Greenspan J.J. Schildkraut E.K. Gordon L. Baer M.S. Arnoff J. Durell Catecholamine metabolism in affective disorders. 3. MHPG and other catecholamine metabolites in patients treated with lithium carbonate J. Psychiat. Res. 7 1970 171 183
15. F.D. Jones J.W. Maas H. Dekirmenjian J.A. Fawcett Urinary catecholamine metabolites during behavioural changes in a patient with manic depressive cycles Science 179 1973 300 302
16. B. Leonard Noradrenaline in basic models of depression Eur. Neuropsychopharmacology 1997 S11 S16 this volume
17. J.W. Maas J. Fawcett H. Dekirmenjian 3-methoxy-4-hydroxy-phenylglycol (MHPG) excretion in depressive states Arch. Gen. Psychiatry 19 1968 129 134
18. J.W. Maas J. Fawcett H. Dekirmenjian Catecholamine metabolism, depressive illness and drug response Arch. Gen. Psychiatry 26 1972 252 262
19. J.W. Maas H. Dekirmenjian F. Jones The identification of depressed patients who have a disorder of NE metabolism and/or disposition Front. Catecholamine Res. 1973 1091 1096
20. J.W. Maas S.H. Koslow M.M. Katz C.L. Bowden R.L. Gibbons P.E. Stokes E. Robins J.M. Davies Pretreatment neuro-transmitter metabolite levels and response to tricyclic antidepressant drugs Am. J. Psychiat. 141 1984 1159 1171
21. H.L. Miller P.L. Delgado R.M. Salomon R. Berman J.H. Krystal G.R. Heninger D.S. Charney Clinical and biochemical effects of catecholamine depletion on antidepressant induced remission of depression Arch. Gen. Psychiatry 53 1996 117 128
22. J. Modai A. Apter M. Golomb J. Wijsenbeek Response to amitriptyline and urinary MHPG in bipolar depressive patients Neuropsychobiology 5 1979 181 184
23. S.A. Montgomery D. James D.B. Montgomery Pharmacological specificity is not the same as clinical selectivity Psychopharmacology 3 1987 179 183
24. S.A. Montgomery H. Dufour S. Brion J. Gailledreau X. Lequeille G. Ferrey P. Moron N. Parant-Lucena L. Singer J.M. Danion J.N. Beuzen M.A. Pierredon The prophylactic efficacy of fluoxetine in unipolar depression Br. J. Psychiatry 153 suppl. 3 1988 69 76
25. S.A. Montgomery G.C. Dunbar Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression Int. Clin. Psychopharmacol. 8 1993 189 195
26. S.A. Montgomery D.L. Dunner G.C. Dunbar Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo Eur. Neuropsychopharmacol. 5 1995 5 13
27. Montgomery, S.A. (1996) SSRIs in the treatment of recurrent depression. Presented at ECNP IX Annual Congress Amsterdam, September 1996
28. J.C. Nelson C.M. Mazure M.B. Bowers P.I. Jatlow A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression Arch. Gen. Psychiatry 48 1991 303 307
29. W.A. Nolan J.J. Van de Putte W.A. Dijken J.S. Kamp B.A. Blansjaar H.J. Kramer J. Haffmans Treatment strategy in depression: non-tricyclic and selective reuptake inhibitors in resistant depression: a double blind partial crossover study on the effects of oxaprotaline and fluvoxamine Acta. Psychiat. Scand. 78 1988 667 668
30. S. Puzynski A. Rode A. Bidzinski S. Mrozek M. Zaluska Failure to correlate urinary MHPG with clinical response to amitriptyline Acta. Psychiatr. Scand. 69 1984 117 120
31. E. Sacchetti E. Smeraldi E. Allaria M. Cagnasso P.A. Biondi MHPG, amitriptyline and depression: a collaborative study A. Frigerio E.L. Ghisalberti Mass Spectroscopy in Drug Metabolism 1977 Plenum Publ Corp New York 215 224
32. A.F. Schatzberg A.H. Rosenbaum P.J. Orsulak W.A. Rohde T. Maruta E.R. Kruger J.O. Cole J.J. Schildkraut Toward a biochemical classification of depressive disorders. III: Pretreatment urinary MHPG levels as predictors of response to maprotiline Psychopharmacology 75 1981 34 38
33. J.J. Schildkraut P.R. Draskoczy E.S. Gerschon P. Reich E.L. Grab Catecholamine metabolism in affective disorders. IV. Preliminary studies of norepinephrine metabolism in depressed patients treated with amitriptyline J. Psychiatr. Res. 9 1972 173 185
34. I.J. Sharma T.A. Venkitasubramanian B.R. Agnihotri 3-MHPG Comparing a non-predictor of antidepressant response to imipramine and choice Hum. Psychopharmacol. 10 1986 S199 S209
35. I.J. Sharma T.A. Venkitasubramanian B.R. Agnihotri 3-MHPG as a non-predictor of antidepressant response to imipramine and electroconvulsive therapy Acta. Psychiatr. Scand. 74 1986 252 254
36. M.H. Teicher C.A. Glod J.O. Cole Antidepressant drugs and the emergence of suicidal tendencies Drug Saf. 8 1993 186 212
37. S.J. Van Den Berg Comparing SSRIs: from chemistry to clinical choice Hum. Psychopharmacol. 10 1995 S199 S209